In the U.S., clinical trials for amyotrophic lateral sclerosis (ALS) do not include enough non-white patients and women to fully represent the disease’s landscape in the real world, a study found.
In the U.S., clinical trials for amyotrophic lateral sclerosis (ALS) do not include enough non-white patients and women to fully represent the disease’s landscape in the real world, a study found.